Article Sidebar

pdf
Date Published: 17/10/2024
Abstract Views: 0
Views pdf: 0
DOI: https://doi.org/10.51298/vmj.v543i2.11426
Issue
Vol. 543 No. 2 (2024)
Section
Các bài báo
How to Cite
Nguyễn, T. M. X., & Nguyễn, T. H. C. (2024). SURVEY ON THE QUALITY OF LIFE OF PSORIATIC PATIENTS TREATED WITH BIOLOGICAL DRUGS. Vietnam Medical Journal, 543(2). https://doi.org/10.51298/vmj.v543i2.11426

SURVEY ON THE QUALITY OF LIFE OF PSORIATIC PATIENTS TREATED WITH BIOLOGICAL DRUGS

Thị Mai Xuân Nguyễn, Thị Hồng Chuyên Nguyễn

Main Article Content

Abstract

Objective: To evaluate patients' quality of life with moderate-severe psoriasis vulgaris treated with biologic drugs. We also aimed to determine any associations between quality of life and the participants' epidemiological and clinical characteristics. Subject and method: A cross-sectional study was conducted to assess the quality of life using the Dermatology Life Quality Index (DLQI) in 148 participants at HCMC Hospital of Dermato–Vereneology from March 2024 to June 2024. Result: The most used biologic drug was Secukinumab (92.5%), and 87.8% of patients were satisfied with the current biologic treatment. Patients treated with biologic drugs showed significant improvement in PASI, BSA, and DLQI scores. The DLQI score after biologic treatment was 3.32 ± 4.69. Most participants had a DLQI ≤ 5 points. Multivariate regression analysis revealed that DLQI was associated with treatment satisfaction, adherence, difficult-to-treat areas such as the scalp, and BSA index. Conclusion: Biological therapy significantly improved the quality of life for patients with psoriasis. Factors such as dissatisfaction with treatment, intermittent treatment, BSA≥ 3, and lesions on the scalp had a negative impact on the quality of life of patients with psoriasis. The research emphasized the role of DLQI as an important index to evaluate in the treatment process for patients.

Article Details

Keywords

Dermatology Life Quality Index, psoriasis, biologics.

References

Boehncke WH, Schön MP. Psoriasis. Lancet. Sep 5 2015;386(9997):983-94. doi:10.1016/ s0140-6736(14)61909-7
2. Min S, Wang D, Xia J, et al. The economic burden and quality of life of patients with psoriasis treated with biologics in China. J Dermatolog Treat. Dec 2023;34(1):2247106. doi:10.1080/09546634.2023.2247106
3. Tsai T-F, Ho J-C, Chen Y-J, et al. Health-related quality of life among patients with moderate-to-severe plaque psoriasis in Taiwan. Dermatologica Sinica. 2018/12/01/ 2018;36(4): 190-195. doi:https://doi.org/ 10.1016/j.dsi. 2018.06.006
4. Valenzuela F, Flores R. Immunogenicity to biological drugs in psoriasis and psoriatic arthritis. Clinics (Sao Paulo). 2021;76:e3015. doi:10.6061/ clinics/2021/e3015
5. Lin TY, See LC, Shen YM, et al. Quality of life in patients with psoriasis in northern Taiwan. Chang Gung Med J. Mar-Apr 2011;34(2):186-96.
6. Golbari NM, van der Walt JM, Blauvelt A, et al. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. J Eur Acad Dermatol Venereol. Feb 2021;35(2):417-421. doi:10.1111/jdv.16966
7. Zampieron A, Buja A, Fusco M, et al. Quality of life in patients with scalp psoriasis. G Ital Dermatol Venereol. Jun 2015;150(3):309-16.
8. Nicolescu AC, Ionescu MA, Constantin MM, et al. Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness. Life (Basel). Dec 7 2022;12(12)doi:10.3390/life12122050